CA
Caris Life Sciences, Inc.
CAI · NASDAQ
$28.50 +10.47% (+$2.70)
1M +31.76%
Market Cap $8.06B
P/E Ratio 76.63x
Div. Yield -
ROE 18.77%
Piotroski F-Score Moderate
5/9Valuation
0 /100
Expensive P/B 13.61x
P/S 8.14x
P/E 76.63x
Growth
100 /100
Growing Rev. growth 46.46%
FCF growth N/A
Book val. growth N/A
Profitability
79 /100
Strong FCF margin 14.80%
Op. margin 15.49%
Gross margin 69.66%
Quality
79 /100
Excellent Asset turnover 0.80x
ROA 8.55%
ROIC 14.69%
Debt
78 /100
Low Net debt/EBITDA -1.38x
Int. coverage 3.24x
Debt/Equity 0.76x
Stability
41 /100
Moderate Profitable years 0
EPS volatility 39.17%
Beta 0.68x
Bulios Scoring opisuje kakovost in preteklost podjetja, ne prihodnjega donosa. Visok rezultat ni nakupni signal. Izvedite več
Vprašajte StockBota o CAI
Online
Sector
Healthcare
Industry
Biotechnology
CEO
David Dean Halbert
Employees
1,846
Headquarters
Irving
Prihajajoči dogodki
04 NOV.
Earnings
Upcoming earnings report